Targeted radionuclide therapy in head and neck cancer

Head and Neck

Volumn 32, Issue 5, 2010, Pages 666-678

  Nestor, Marika V ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Antibody; Head and neck squamous cell carcinoma; Radionuclide; Targeting; Therapy

Indexed keywords

ANTIGEN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BIVATUZUMAB RE 186; CETUXIMAB; MONOCLONAL ANTIBODY U36 RE 186; PANITUMUMAB; RADIOISOTOPE; UNCLASSIFIED DRUG; ZALUTUMUMAB;

ANTINEOPLASTIC ACTIVITY; BONE MARROW TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DRUG BINDING; DRUG DOSE ESCALATION; HEAD AND NECK CARCINOMA; HUMAN; IMMUNOSCINTIGRAPHY; ISOTOPE LABELING; LEUKOPENIA; LUNG CANCER; LUNG NON SMALL CELL CANCER; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; STOMATITIS; THROMBOCYTOPENIA;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS AS TOPIC; HEAD AND NECK NEOPLASMS; HUMANS; RADIOISOTOPES; RADIOTHERAPY; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77951602936     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21243     Document Type: Review

References (121)

1. Chames P, Van Regenmortel M, Weiss E, Baty D. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol. 2009;157:220-233.
2. Dimitrov DS, Marks JD. Therapeutic antibodies: current state and future trends - is a paradigm change coming soon? Methods Mol Biol 2009;525:xiii,1-27.
3. Potamianos S, Varvarigou AD, Archimandritis SC. Radioimmunoscintigraphy and radioimmunotherapy in cancer: principles and application. Anticancer Res 2000;20:925-948. (Pubitemid 30240657)
4. Carlsson J, Forssell Aronsson E, Hietala SO, Stigbrand T, Tennvall J. Tumour therapy with radionuclides: assessment of progress and problems. Radiother Oncol 2003;66:107-117. (Pubitemid 36321806)
5. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
6. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94:153-156.
7. Chin D, Boyle GM, Porceddu S, Theile DR, Parsons PG, Coman WB. Head and neck cancer: past, present and future. Expert Rev Anticancer Ther 2006;6:1111-1118. (Pubitemid 44203388)
8. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116-1127.
9. Burri RJ, Lee NY. Concurrent chemotherapy and radiotherapy for head and neck cancer. Expert Rev Anticancer Ther 2009;9:293-302.
10. Laramore GE. Role of particle radiotherapy in the management of head and neck cancer. Curr Opin Oncol 2009;21:224-231.
11. Saba NF, Khuri FR. Optimizing systemic therapy in squamous cell carcinoma of the head and neck with a focus on targeted agents. Curr Opin Oncol 2009;21:232-237.
12. Taneja C, Allen H, Koness RJ, Radie-Keane K, Wanebo HJ. Changing patterns of failure of head and neck cancer. Arch Otolaryngol Head Neck Surg 2002;128:324-327. (Pubitemid 34218589)
13. Corvo R. Evidence-based radiation oncology in head and neck squamous cell carcinoma. Radiother Oncol 2007;85:156-170. (Pubitemid 47562578)
14. Langer CJ. Targeted therapy in head and neck cancer: state of the art 2007 and review of clinical applications. Cancer 2008;112:2635-2645.
15. de Bree R, Kuik DJ, Quak JJ, et al. The impact of tumour volume and other characteristics on uptake of radiolabelled monoclonal antibodies in tumour tissue of head and neck cancer patients. Eur J Nucl Med 1998;25:1562-1565.
16. Funaro A, Horenstein AL, Santoro P, Cinti C, Gregorini A, Malavasi F. Monoclonal antibodies and therapy of human cancers. Biotechnol Adv 2000;18:385-401.
17. Eshel R, Zanin A, Kapon D, et al. Human Ly-6 antigen E48 (Ly-6D) regulates important interaction parameters between endothelial cells and head-and-neck squamous carcinoma cells. Int J Cancer 2002;98:803-810. (Pubitemid 34286673)
18. Rubinfeld B, Upadhyay A, Clark SL, et al. Identification and immunotherapeutic targeting of antigens induced by chemotherapy. Nat Biotechnol 2006;24:205-209. (Pubitemid 43221705)
19. Brakenhoff RH, Gerretsen M, Knippels EM, et al. The human E48 antigen, highly homologous to the murine Ly-6 antigen ThB, is a GPI-anchored molecule apparently involved in keratinocyte cell-cell adhesion. J Cell Biol 1995;129:1677-1689.
20. de Bree R, Roos JC, Quak JJ, Den Hollander W, Snow GB, Van Dongen GA. Clinical screening of monoclonal antibodies 323/A3, cSF-25 and K928 for suitability of targetting tumours in the upper aerodigestive and respiratory tract. Nucl Med Commun 1994;15:613-627. (Pubitemid 24259775)
21. Terpe HJ, Storkel S, Zimmer U, et al. Expression of CD44 isoforms in renal cell tumors. Positive correlation to tumor differentiation. Am J Pathol 1996;148:453-463. (Pubitemid 26056730)
22. Gunthert U, Hofmann M, Rudy W, et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991;65:13-24. (Pubitemid 121001209)
23. Prince ME, Sivanandan R, Kaczorowski A, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A 2007;104:973-978. (Pubitemid 46154721)
24. Mack B, Gires O. CD44s and CD44v6 expression in head and neck epithelia. PLoS ONE 2008;3:e3360.
25. Heider KH, Kuthan H, Stehle G, Munzert G. CD44v6: a target for antibody-based cancer therapy. Cancer Immunol Immunother 2004;53:567-579. (Pubitemid 38858330)
26. Heider KH, Sproll M, Susani S, et al. Characterization of a high-affinity monoclonal antibody specific for CD44v6 as candidate for immunotherapy of squamous cell carcinomas. Cancer Immunol Immunother 1996;43:245-253. (Pubitemid 26426258)
27. Jung K, Lein M, Weiss S, Schnorr D, Henke W, Loening S. Soluble CD44 molecules in serum of patients with prostate cancer and benign prostatic hyperplasia. Eur J Cancer 1996;32A:627-630. (Pubitemid 26155158)
28. Van Hal NL, Van Dongen GA, Ten Brink CB, et al. Evaluation of soluble CD44v6 as a potential serum marker for head and neck squamous cell carcinoma. Clin Cancer Res 1999;5:3534-3541.
29. Heider KH, Mulder JW, Ostermann E, et al. Splice variants of the cell surface glycoprotein CD44 associated with metastatic tumour cells are expressed in normal tissues of humans and cynomolgus monkeys. Eur J Cancer 1995;31A:2385-2391. (Pubitemid 26050584)
30. Schrijvers AH, Quak JJ, Uyterlinde AM, et al. MAb U36, a novel monoclonal antibody successful in immunotargeting of squamous cell carcinoma of the head and neck. Cancer Res 1993;53:4383-4390. (Pubitemid 24146794)
31. Tijink BM, Buter J, de Bree R, et al. A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res 2006;12:6064-6072. (Pubitemid 44703770)
32. Börjesson PK, Postema EJ, Roos JC, et al. Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma. Clin Cancer Res 2003;9:3961S-3972S.
33. 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck. J Nucl Med 2000;41:1999-2010.
34. Walker RA. The erbB/HER type 1 tyrosine kinase receptor family. J Pathol 1998;185:234-235. (Pubitemid 28320043)
35. Rikimaru K, Tadokoro K, Yamamoto T, Enomoto S, Tsuchida N. Gene amplification and overexpression of epidermal growth factor receptor in squamous cell carcinoma of the head and neck. Head Neck 1992;14:8-13.
36. Santini J, Formento JL, Francoual M, et al. Characterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas. Head Neck 1991;13:132-139.
37. Sok JC, Coppelli FM, Thomas SM, et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 2006;12:5064-5073. (Pubitemid 44453332)
38. Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002;62:7350-7356. (Pubitemid 36025259)
39. Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 2004;59(2 Suppl):21-26. (Pubitemid 38610223)
40. Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006;33:369-385. (Pubitemid 44142736)
41. Akimoto T, Hunter NR, Buchmiller L, Mason K, Ang KK, Milas L. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res 1999;5:2884-2890. (Pubitemid 29493967)
42. Dunn WA, Connolly TP, Hubbard AL. Receptor-mediated endocytosis of epidermal growth factor by rat hepatocytes: receptor pathway. J Cell Biol 1986;102:24-36. (Pubitemid 16155550)
43. Gladhaug IP, Refsnes M, Christoffersen T. Regulation of surface expression of high-affinity receptors for epidermal growth factor (EGF) in hepatocytes by hormones, differentiating agents, and phorbol ester. Dig Dis Sci 1992;37:233-239.
44. Neri D, Bicknell R. Tumour vascular targeting. Nat Rev Cancer 2005;5:436-446.
45. Jain RK. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Semin Oncol 2002;29(6 Suppl 16):3-9.
46. Lothaire P, de Azambuja E, Dequanter D, et al. Molecular markers of head and neck squamous cell carcinoma: promising signs in need of prospective evaluation. Head Neck 2006;28:256-269. (Pubitemid 43269893)
47. Carnemolla B, Balza E, Siri A, et al. A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors. J Cell Biol 1989;108:1139-1148. (Pubitemid 19083757)
48. Birchler MT, Milisavlijevic D, Pfaltz M, et al. Expression of the extra domain B of fibronectin, a marker of angiogenesis, in head and neck tumors. Laryngoscope 2003;113:1231-1237. (Pubitemid 36835572)
49. Hasina R, Whipple ME, Martin LE, Kuo WP, Ohno-Machado L, Lingen MW. Angiogenic heterogeneity in head and neck squamous cell carcinoma: biological and therapeutic implications. Lab Invest 2008;88:342-353. (Pubitemid 351432778)
50. Brack SS, Silacci M, Birchler M, Neri D. Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C. Clin Cancer Res 2006;12:3200-3208. (Pubitemid 43837370)
51. Andratschke M, Hagedorn H, Luebbers CW, et al. Limited suitability of EpCAM for molecular staging of tumor borders in head and neck cancer. Anticancer Res 2006;26:153-158. (Pubitemid 43210323)
52. De Herdt MJ, Baatenburg de Jong RJ. HGF and c-MET as potential orchestrators of invasive growth in head and neck squamous cell carcinoma. Front Biosci 2008;13:2516-2526. (Pubitemid 351599701)
53. Barnes CJ, Ohshiro K, Rayala SK, El-Naggar AK, Kumar R. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer. Clin Cancer Res 2007;13:4291-4299. (Pubitemid 47105993)
54. Hindermann W, Berndt A, Borsi L, et al. Synthesis and protein distribution of the unspliced large tenascin-C isoform in oral squamous cell carcinoma. J Pathol 1999;189:475-480.
55. Binz HK, Amstutz P, Kohl A, et al. High-affinity binders selected from designed ankyrin repeat protein libraries. Nat Biotechnol 2004;22:575-582. (Pubitemid 38590636)
56. Malabarba MG, Milia E, Faretta M, Zamponi R, Pelicci PG, Di Fiore PP. A repertoire library that allows the selection of synthetic SH2s with altered binding specificities. Oncogene 2001;20:5186-5194. (Pubitemid 32844047)
57. Schneider S, Buchert M, Georgiev O, et al. Mutagenesis and selection of PDZ domains that bind new protein targets. Nat Biotechnol 1999;17:170-175. (Pubitemid 29072542)
58. Beste G, Schmidt FS, Stibora T, Skerra A. Small antibody-like proteins with prescribed ligand specificities derived from the lipocalin fold. Proc Natl Acad Sci U S A 1999;96:1898-1903. (Pubitemid 29117839)
59. Koide A, Bailey CW, Huang X, Koide S. The fibronectin type III domain as a scaffold for novel binding proteins. J Mol Biol 1998;284:1141-1151. (Pubitemid 28558562)
60. Nord K, Gunneriusson E, Ringdahl J, Stahl S, Uhlen M, Nygren PA. Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain. Nat Biotechnol 1997;15:772-777. (Pubitemid 27329481)
61. Börjesson PK, Postema EJ, de Bree R, et al. Radioimmunodetection and radioimmunotherapy of head and neck cancer. Oral Oncol 2004;40:761-772. (Pubitemid 39061090)
62. Paganelli G, Orecchia R, Jereczek-Fossa B, et al. Combined treatment of advanced oropharyngeal cancer with external radiotherapy and three-step radioimmunotherapy. Eur J Nucl Med 1998;25:1336-1339. (Pubitemid 28446063)
63. Tranter RM, Fairweather DS, Bradwell AR, Dykes PW, Watson-James S, Chandler S. The detection of squamous cell tumours of the head and neck using radio-labelled antibodies. J Laryngol Otol 1984;98:71-74.
64. Kairemo KJ, Hopsu EV. Imaging of tumours in the parotid region with indium-111 labelled monoclonal antibody reacting with carcinoembryonic antigen. Acta Oncol 1990;29:539-543.
65. Kairemo KJ, Hopsu EV. Imaging of pharyngeal and laryngeal carcinomas with indium-111-labeled monoclonal anti-CEA antibodies. Laryngoscope 1990;100:1077-1082. (Pubitemid 20339048)
66. Timon CI, McShane D, Hamilton D, Walsh MA. Head and neck cancer localization with indium labelled carcinoembryonic antigen: a pilot project. J Otolaryngol 1991;20:283-287.
67. De Rossi G, Maurizi M, Almadori G, et al. The contribution of immunoscintigraphy to the diagnosis of head and neck tumours. Nucl Med Commun 1997;18:10-16. (Pubitemid 27110166)
68. Soo KC, Ward M, Roberts KR, et al. Radioimmunoscintigraphy of squamous carcinomas of the head and neck. Head Neck Surg 1987;9:349-352.
69. Schechter NR, Wendt RE 3rd, Yang DJ, et al. Radiation dosimetry of 99mTc-labeled C225 in patients with squamous cell carcinoma of the head and neck. J Nucl Med 2004;45:1683-1687. (Pubitemid 47618475)
70. Baum RP, Adams S, Kiefer J, et al. A novel technetium-99m labeled monoclonal antibody (174H.64) for staging head and neck cancer by immuno-SPECT. Acta Oncol 1993;32:747-751. (Pubitemid 24059883)
71. Heissler E, Grunert B, Barzen G, et al. Radioimmunoscintigraphy of squamous cell carcinoma in the head and neck region. Int J Oral Maxillofac Surg 1994;23:149-152. (Pubitemid 124012647)
72. Adamietz IA, Baum RP, Schemman F, et al. Improvement of radiation treatment planning in squamous-cell head and neck cancer by immuno-SPECT. J Nucl Med 1996;37:1942-1946. (Pubitemid 26428358)
73. 2. Cancer Res 1992;52:2569-2574.
74. 2. J Nucl Med 1994;35:775-783.
75. 2 in patients with head and neck cancer. Clin Cancer Res 1995;1:277-286.
76. de Bree R, Roos JC, Verel I, van Dongen GA, Snow GB. Radioimmunodiagnosis of lymph node metastases in head and neck cancer. Oral Dis 2003;9:241-248. (Pubitemid 37047632)
77. de Bree R, Roos JC, Quak JJ, den Hollander W, Snow GB, van Dongen GA. Radioimmunoscintigraphy and biodistribution of technetium-99m-labeled monoclonal antibody U36 in patients with head and neck cancer. Clin Cancer Res 1995;1:591-598.
78. Börjesson PK, Jauw YW, Boellaard R, et al. Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients. Clin Cancer Res 2006;12:2133-2140.
79. 186Re-labeled chimeric monoclonal antibody U36 radioimmunotherapy in a phase I dose escalation study. Clin Cancer Res 2002;8:3401-3406.
80. Stroomer JW, Roos JC, Sproll M, et al. Safety and biodistribution of 99mTechnetium-labeled anti-CD44v6 monoclonal antibody BIWA 1 in head and neck cancer patients. Clin Cancer Res 2000;6:3046-3055. (Pubitemid 30637727)
81. Colnot DR, Roos JC, de Bree R, et al. Safety, biodistribution, pharmacokinetics, and immunogenicity of 99mTc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 2003;52:576-582. (Pubitemid 37056133)
82. Birchler MT, Thuerl C, Schmid D, et al. Immunoscintigraphy of patients with head and neck carcinomas, with an anti-angiogenetic antibody fragment. Otolaryngol Head Neck Surg 2007;136:543-548. (Pubitemid 46533872)
83. Verel I, Heider KH, Siegmund M, et al. Tumor targeting properties of monoclonal antibodies with different affinity for target antigen CD44V6 in nude mice bearing head-and-neck cancer xenografts. Int J Cancer 2002;99:396-402. (Pubitemid 34495853)
84. Brakenhoff RH, van Gog FB, Looney JE, van Walsum M, Snow GB, van Dongen GA. Construction and characterization of the chimeric monoclonal antibody E48 for therapy of head and neck cancer. Cancer Immunol Immunother 1995;40:191-200.
85. Van Hal NL, Van Dongen GA, Rood-Knippels EM, Van Der Valk P, Snow GB, Brakenhoff RH. Monoclonal antibody U36, a suitable candidate for clinical immunotherapy of squamous-cell carcinoma, recognizes a CD44 isoform. Int J Cancer 1996;68:520-527.
86. Marshall J. Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. Cancer 2006;107:1207-1218. (Pubitemid 44452768)
87. Dutta PR, Maity A. Cellular responses to EGFR inhibitors and their relevance to cancer therapy. Cancer Lett 2007;254:165-177. (Pubitemid 47161103)
88. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 2002;7(Suppl 4):2-8. (Pubitemid 34977157)
89. Mendelsohn J, Fan Z. Epidermal growth factor receptor family and chemosensitization. J Natl Cancer Inst 1997;89:341-343. (Pubitemid 27102599)
90. Perez-Soler R, Donato NJ, Shin DM, et al. Tumor epidermal growth factor receptor studies in patients with non-small-cell lung cancer or head and neck cancer treated with monoclonal antibody RG 83852. J Clin Oncol 1994;12:730-739. (Pubitemid 24110912)
91. Modjtahedi H, Dean C. Monoclonal antibodies to the EGF receptor act as betacellulin antagonists. Biochem Biophys Res Commun 1996;221:625-630. (Pubitemid 26160062)
92. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-578. (Pubitemid 43209104)
93. Diaz Miqueli A, Blanco R, Garcia B, et al. Biological activity in vitro of anti-epidermal growth factor receptor monoclonal antibodies with different affinities. Hybridoma (Larchmt) 2007;26:423-431.
94. Cruz JJ, Ocana A, Del Barco E, Pandiella A. Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancer. Ann Oncol 2007;18:421-430. (Pubitemid 46359619)
95. Fan Z, Baselga J, Masui H, Mendelsohn J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 1993;53:4637-4642. (Pubitemid 23304392)
96. Fan Z, Lu Y, Wu X, Mendelsohn J. Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J Biol Chem 1994;269:27595-27602. (Pubitemid 24346592)
97. Prewett M, Rockwell P, Rockwell RF, et al. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. J Immunother Emphasis Tumor Immunol 1996;19:419-427. (Pubitemid 127495289)
98. Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 2000;6:2166-2174.
99. Bianco C, Bianco R, Tortora G, et al. Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. Clin Cancer Res 2000;6:4343-4350.
100. Milas L, Mason K, Hunter N, et al. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 2000;6:701-708.
101. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999;59:1935-1940.
102. Gold KA, Lee HY, Kim ES. Targeted therapies in squamous cell carcinoma of the head and neck. Cancer 2009;115:922-935.
103. Berndorff D, Borkowski S, Sieger S, et al. Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: identification of the best-suited radioimmunoconjugate. Clin Cancer Res 2005;11:7053s-7063s. (Pubitemid 41428704)
104. Borsi L, Balza E, Bestagno M, et al. Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int J Cancer 2002;102:75-85.
105. Sharkey RM, Blumenthal RD, Behr TM, et al. Selection of radioimmunoconjugates for the therapy of well-established or micrometastatic colon carcinoma. Int J Cancer 1997;72:477-485.
106. Koppe MJ, Postema EJ, Aarts F, Oyen WJ, Bleichrodt RP, Boerman OC. Antibody-guided radiation therapy of cancer. Cancer Metastasis Rev 2005;24:539-567.
107. Zalutsky MR, Vaidyanathan G. Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy. Curr Pharm Des 2000;6:1433-1455.
108. Persson MI, Gedda L, Jensen HJ, Lundqvist H, Malmstrom PU, Tolmachev V. Astatinated trastuzumab, a putative agent for radionuclide immunotherapy of ErbB2-expressing tumours. Oncol Rep 2006;15:673-680.
109. Nestor M, Andersson K, Lundqvist H. Characterization of (111)In and (177)Lu-labeled antibodies binding to CD44v6 using a novel automated radioimmunoassay. J Mol Recognit 2008;21:179-183.
110. Nestor M, Persson M, Cheng J, et al. Biodistribution of the chimeric monoclonal antibody U36 radioiodinated with a closo-dodecaborate-containing linker. Comparison with other radioiodination methods. Bioconjug Chem 2003;14:805-810.
111. Nestor M, Persson M, van Dongen GA, et al. In vitro evaluation of the astatinated chimeric monoclonal antibody U36, a potential candidate for treatment of head and neck squamous cell carcinoma. Eur J Nucl Med Mol Imaging 2005;32:1296-1304.
112. 111In-labeled monoclonal antibody. Tumour Biol 2008;29:137-144.
113. Colnot DR, Quak JJ, Roos JC, et al. Radioimmunotherapy in patients with head and neck squamous cell carcinoma: initial experience. Head Neck 2001;23:559-565. (Pubitemid 32565529)
114. 186Re-labeled bivatuzumab in patients with head and neck cancer. J Nucl Med 2003;44:1690-1699.
115. 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature. J Nucl Med 2006;47:1127-1135.
116. van Gog FB, Brakenhoff RH, Stigter-van Walsum M, Snow GB, van Dongen GA. Perspectives of combined radioimmunotherapy and anti-EGFR antibody therapy for the treatment of residual head and neck cancer. Int J Cancer 1998;77:13-18. (Pubitemid 28308545)
117. 131I-labelled anti-EpCAM monoclonal antibody. Anticancer Res 2007;27:431-436.
118. van Dongen GA, Visser GW, Lub-de Hooge MN, de Vries EG, Perk LR. Immuno-PET: a navigator in monoclonal antibody development and applications. Oncologist 2007;12:1379-1389.
119. Behr TM, Griesinger F, Riggert J, et al. High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Results of a pilot study. Cancer 2002;94(4 Suppl):1363-1372. (Pubitemid 34150900)
120. Goldenberg DM, Sharkey RM. Novel radiolabeled antibody conjugates. Oncogene 2007;26:3734-3744.
121. Shirai K, O'Brien PE. Molecular targets in squamous cell carcinoma of the head and neck. Curr Treat Options Oncol 2007;8:239-251.